Cargando…
Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches
Cancer is a leading cause of death which imposes a substantial financial burden. Among the several mechanisms involved in cancer progression, imbalance of immune cell‐derived factors such as cytokines and chemokines plays a central role. IL‐25, as a member of the IL‐17 cytokine subfamily, exerts a p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335817/ https://www.ncbi.nlm.nih.gov/pubmed/34128588 http://dx.doi.org/10.1002/cam4.4060 |
_version_ | 1783733201311629312 |
---|---|
author | Gowhari Shabgah, Arezoo Amir, Azwar Gardanova, Zhanna R. Olegovna Zekiy, Angelina Thangavelu, Lakshmi Ebrahimi Nik, Maryam Ahmadi, Majid Gholizadeh Navashenaq, Jamshid |
author_facet | Gowhari Shabgah, Arezoo Amir, Azwar Gardanova, Zhanna R. Olegovna Zekiy, Angelina Thangavelu, Lakshmi Ebrahimi Nik, Maryam Ahmadi, Majid Gholizadeh Navashenaq, Jamshid |
author_sort | Gowhari Shabgah, Arezoo |
collection | PubMed |
description | Cancer is a leading cause of death which imposes a substantial financial burden. Among the several mechanisms involved in cancer progression, imbalance of immune cell‐derived factors such as cytokines and chemokines plays a central role. IL‐25, as a member of the IL‐17 cytokine subfamily, exerts a paradoxical role in cancer, including tumor supportive and tumor suppressive. Hence, we have tried to clarify the role of IL‐25 and its receptor in tumor progression and cancer prognosis. It has been confirmed that IL‐25 exerts a tumor‐suppressive role through inducing infiltration of eosinophils and B cells into the tumor microenvironment and activating the apoptotic pathways. In contrast, the tumor‐supportive function has been implemented by activating inflammatory cascades, promoting cell cycle, and inducing type‐2 immune responses. Since IL‐25 has been dysregulated in tumor tissues and this dysregulation is involved in cancer development, its examination can be used as a tumor diagnostic and prognostic biomarker. Moreover, IL‐25‐based therapeutic approaches have shown promising results in cancer inhibition. In cancers in which IL‐25 has a tumor‐suppressive function, employing IL‐25‐enhancing approaches, such as Virulizin(®) and dihydrobenzofuran administration, has potentially inhibited tumor cell growth. On the other hand, in the case of IL‐25‐dependent tumor progression, using IL‐25 blocking methods, including anti‐IL‐25 antibodies, might be a complementary approach to the other anticancer agent. Collectively, it is hoped, IL‐25 might be a promising target in cancer treatment. |
format | Online Article Text |
id | pubmed-8335817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83358172021-08-09 Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches Gowhari Shabgah, Arezoo Amir, Azwar Gardanova, Zhanna R. Olegovna Zekiy, Angelina Thangavelu, Lakshmi Ebrahimi Nik, Maryam Ahmadi, Majid Gholizadeh Navashenaq, Jamshid Cancer Med Cancer Biology Cancer is a leading cause of death which imposes a substantial financial burden. Among the several mechanisms involved in cancer progression, imbalance of immune cell‐derived factors such as cytokines and chemokines plays a central role. IL‐25, as a member of the IL‐17 cytokine subfamily, exerts a paradoxical role in cancer, including tumor supportive and tumor suppressive. Hence, we have tried to clarify the role of IL‐25 and its receptor in tumor progression and cancer prognosis. It has been confirmed that IL‐25 exerts a tumor‐suppressive role through inducing infiltration of eosinophils and B cells into the tumor microenvironment and activating the apoptotic pathways. In contrast, the tumor‐supportive function has been implemented by activating inflammatory cascades, promoting cell cycle, and inducing type‐2 immune responses. Since IL‐25 has been dysregulated in tumor tissues and this dysregulation is involved in cancer development, its examination can be used as a tumor diagnostic and prognostic biomarker. Moreover, IL‐25‐based therapeutic approaches have shown promising results in cancer inhibition. In cancers in which IL‐25 has a tumor‐suppressive function, employing IL‐25‐enhancing approaches, such as Virulizin(®) and dihydrobenzofuran administration, has potentially inhibited tumor cell growth. On the other hand, in the case of IL‐25‐dependent tumor progression, using IL‐25 blocking methods, including anti‐IL‐25 antibodies, might be a complementary approach to the other anticancer agent. Collectively, it is hoped, IL‐25 might be a promising target in cancer treatment. John Wiley and Sons Inc. 2021-06-15 /pmc/articles/PMC8335817/ /pubmed/34128588 http://dx.doi.org/10.1002/cam4.4060 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Biology Gowhari Shabgah, Arezoo Amir, Azwar Gardanova, Zhanna R. Olegovna Zekiy, Angelina Thangavelu, Lakshmi Ebrahimi Nik, Maryam Ahmadi, Majid Gholizadeh Navashenaq, Jamshid Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
title | Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
title_full | Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
title_fullStr | Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
title_full_unstemmed | Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
title_short | Interleukin‐25: New perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
title_sort | interleukin‐25: new perspective and state‐of‐the‐art in cancer prognosis and treatment approaches |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335817/ https://www.ncbi.nlm.nih.gov/pubmed/34128588 http://dx.doi.org/10.1002/cam4.4060 |
work_keys_str_mv | AT gowharishabgaharezoo interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT amirazwar interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT gardanovazhannar interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT olegovnazekiyangelina interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT thangavelulakshmi interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT ebrahiminikmaryam interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT ahmadimajid interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches AT gholizadehnavashenaqjamshid interleukin25newperspectiveandstateoftheartincancerprognosisandtreatmentapproaches |